ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention
May 14 2024 - 7:57AM
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical
stage specialty biopharmaceutical company developing first-in-class
drugs for the treatment of renal and inflammatory diseases with
high unmet medical needs, announces that Stephen C. Glover,
Co-Founder, Chairman, Chief Executive Officer, and President, will
participate in the 2024 BIO International Convention being held
June 3 - 6, 2024 in San Diego, California.
Details for the event are as follows:
Event: |
2024 BIO
International Convention |
Date: |
Monday, June 3 through Thursday June 6, 2024 |
Location: |
San Diego Convention Center |
Registration: |
https://convention.bio.org/registration |
|
|
“We are pleased to have the opportunity to meet with our
colleagues at the 2024 BIO International Convention as we advance
development of our two platform technologies,” stated Mr. Glover.
“ZyVersa has made considerable progress in advancing development of
our two lead candidates. A Phase 2a clinical trial with Cholesterol
Efflux MediatorTM VAR 200 is on target to be initiated in the first
half of this year in patients with diabetic kidney disease, and
preclinical studies for indication expansion are underway with
Inflammasome ASC Inhibitor IC 100 for atherosclerosis, obesity, and
Parkinson’s disease. Near-term read outs are expected for
atherosclerosis and obesity. Likewise, we plan to file an IND for
IC 100 by the end of year, and to initiate a Phase 1 trial in
Q1-2025. To learn more about our differentiated product pipeline,
please schedule a one-on-one meeting through the conference
portal.”
About ZyVersa Therapeutics, Inc.
ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty
biopharmaceutical company leveraging advanced, proprietary
technologies to develop first-in-class drugs for patients with
renal and inflammatory diseases who have significant unmet medical
needs. The Company is currently advancing a therapeutic development
pipeline with multiple programs built around its two proprietary
technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment
of kidney diseases, and Inflammasome ASC Inhibitor IC 100,
targeting damaging inflammation associated with numerous CNS and
peripheral inflammatory diseases. For more information, please
visit zyversa.com.
Cautionary Statement Regarding Forward-Looking
Statements
Certain statements contained in this press release regarding
matters that are not historical facts, are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995. These include statements regarding
management’s intentions, plans, beliefs, expectations, or forecasts
for the future, and, therefore, you are cautioned not to place
undue reliance on them. No forward-looking statement can be
guaranteed, and actual results may differ materially from those
projected. ZyVersa Therapeutics, Inc. (“ZyVersa”) uses words such
as “anticipates,” “believes,” “plans,” “expects,” “projects,”
“future,” “intends,” “may,” “will,” “should,” “could,” “estimates,”
“predicts,” “potential,” “continue,” “guidance,” and similar
expressions to identify these forward-looking statements that are
intended to be covered by the safe-harbor provisions. Such
forward-looking statements are based on ZyVersa’s expectations and
involve risks and uncertainties; consequently, actual results may
differ materially from those expressed or implied in the statements
due to a number of factors, including ZyVersa’s plans to develop
and commercialize its product candidates, the timing of initiation
of ZyVersa’s planned preclinical and clinical trials; the timing of
the availability of data from ZyVersa’s preclinical and clinical
trials; the timing of any planned investigational new drug
application or new drug application; ZyVersa’s plans to research,
develop, and commercialize its current and future product
candidates; the clinical utility, potential benefits and market
acceptance of ZyVersa’s product candidates; ZyVersa’s
commercialization, marketing and manufacturing capabilities and
strategy; ZyVersa’s ability to protect its intellectual property
position; and ZyVersa’s estimates regarding future revenue,
expenses, capital requirements and need for additional
financing.
New factors emerge from time-to-time, and it is not possible for
ZyVersa to predict all such factors, nor can ZyVersa assess the
impact of each such factor on the business or the extent to which
any factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking
statements. Forward-looking statements included in this press
release are based on information available to ZyVersa as of the
date of this press release. ZyVersa disclaims any obligation to
update such forward-looking statements to reflect events or
circumstances after the date of this press release, except as
required by applicable law.
This press release does not constitute an offer to sell, or the
solicitation of an offer to buy, any securities.
Corporate, Media, IR ContactKaren CashmereChief
Commercial Officerkcashmere@zyversa.com786-251-9641
ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From Jun 2024 to Jul 2024
ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From Jul 2023 to Jul 2024